Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Sentinel lymph node mapping in early-stage cervical cancer - A national prospective multicenter study (SENTIREC trial)

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Prognostic value of the 2018 FIGO staging system for cervical cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Assessment of recurrence rate and risk factors of relapse in stage in IA vulvar carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Assessment of recurrence rate and risk factors of relapse in stage in IA vulvar carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • Sara Elisabeth Sponholtz
  • Ole Mogensen
  • Malene Grubbe Hildebrandt
  • Doris Schledermann
  • Erik Parner
  • Algirdas Markauskas
  • Ligita Paskeviciute Frøding
  • Katrine Fuglsang
  • Mie Holm Vilstrup
  • Sarah Marie Bjørnholt
  • Pernille Tine Jensen
Vis graf over relationer

OBJECTIVES: Sentinel lymph node (SLN) mapping may replace staging radical pelvic lymphadenectomy in women with early-stage cervical cancer. In a national multicenter setting, we evaluated SLN mapping in women with early-stage cervical cancer and investigated the accuracy of SLN mapping and FDG-PET/CT in tumors >20 mm.

METHODS: We prospectively included women with early-stage cervical cancer from March 2017-January 2021 to undergo SLN mapping. Women with tumors >20 mm underwent completion pelvic lymphadenectomy and removal of FDG-PET/CT positive nodes. We determined SLN detection rates, incidence of nodal disease, sensitivity and negative predictive value (NPV) of SLN mapping, and the sensitivity, specificity, NPV, and positive predictive value (PPV) of FDG-PET/CT.

RESULTS: We included 245 women, and 38 (15.5%) had nodal metastasis. The SLN detection rate was 96.3% (236/245), with 82.0% (201/245) bilateral detection. In a stratified analysis of 103 women with tumors >20 mm, 27 (26.2%) had nodal metastases. The sensitivity of SLN mapping adhering to the algorithm was 96.3% (95% CI 81.0-99.9%) and the NPV 98.7% (95% CI 93.0-100%). For FDG-PET/CT imaging the sensitivity was 14.8% (95% CI 4.2-33.7%), the specificity 85.5% (95% CI 75.6-92.5%), the NPV 73.9% (95% CI 63.4-82.7%), and the PPV 26.7% (95% CI 7.8-55.1%).

CONCLUSIONS: SLN mapping seems to be an adequate staging procedure in early-stage cervical cancer tumors ≤20 mm. In tumors >20 mm, SLN mapping is highly sensitive but demands full adherence to the SLN algorithm. We recommend completion pelvic lymphadenectomy in tumors >20 mm until the oncological safety is established. FDG-PET/CT for nodal staging of women with early-stage cervical cancer seems limited.

OriginalsprogEngelsk
TidsskriftGynecologic Oncology
Vol/bind162
Udgave nummer3
Sider (fra-til)546-554
Antal sider9
ISSN0090-8258
DOI
StatusUdgivet - sep. 2021

Bibliografisk note

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

ID: 73458103